A reported gene-editing death in China adds to scrutiny around the clinical safety of investigational genome editing approaches. Two weeks after the disclosure of a gene editing death involving a 6-year-old girl treated for Snijders Blok-Campeau syndrome, Chinese company Huidagene Therapeutics disclosed the death of another child receiving its DMD gene editing therapy, HG-302. The disclosure highlights how closely regulators and the market track adverse events in gene editing, particularly as companies attempt to translate cutting-edge platform promises into first-in-human outcomes. It also emphasizes how rapidly patient safety signals can reshape trial programs and investor perception. For biotech stakeholders, the latest update reinforces the importance of transparent safety reporting, durable monitoring protocols, and clear risk management as genome editing expands beyond early feasibility studies.